NTLA vs BEAM
NTLA and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $1.49B | $2.62B |
| P/B | — | 2.25 |
| P/S | 22.1x | 18.8x |
| Revenue | — | $164.01M(TTM) |
| Revenue growth (YoY) | 16.9% | 120.0% |
| Net income | — | -$65.98M(TTM) |
| Earnings growth (YoY) | 20.5% | 78.8% |
| EPS, diluted | — | $-0.49(TTM) |
| EBIT margin | -651.7% | -274.6% |
| ROE | -66.5% | -6.9% |
| ROIC | — | -39.3% |
| 1y total return | -8.2% | +29.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs BEAM
| Metric | NTLA | BEAM |
|---|---|---|
| End value | $7.6K | $13.6K |
| Total return | -24.5% | +36.1% |
| CAGR | -4.2% | +4.9% |
| Volatility | 83.6% | 80.1% |
| Sharpe | 0.32 | 0.41 |
| Sortino | 0.48 | 0.62 |
| Max drawdown | -96.5% | -89.1% |
Based on 1629 common trading days, 2020-02-06 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)